|
Modeling androgen-independent prostate cancer in mutant mice
|
1R01CA115717-01A2
|
$293,554
|
Abate-Shen, Cory
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A Mouse Model for Prostate Cancer
|
5U01CA084294-09
|
$1,212,233
|
Abate-Shen, Cory
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
SPORE in Pancreatic Cancer
|
5P20CA101936-05
|
$1,042,511
|
ABBRUZZESE, JAMES
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Mechanisms of CTL-Mediated Antitumor Activity In Vivo in Mouse Models of Active a
|
Z01 BC 009029
|
$191,496
|
Abrams, Scott
|
CCR (NCI)
|
|
Mechanisms of Tumor Escape and Metastatic Development in Mouse Models of Experime
|
Z01 SC 010371
|
$191,496
|
Abrams, Scott
|
CCR (NCI)
|
|
Optical Probes & Methods for Imaging Integrin Expression
|
5R01CA109754-04
|
$570,346
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Washington University Small Animal Imaging Resource
|
5U24CA083060-09
|
$645,635
|
ACKERMAN, JOSEPH
|
WASHINGTON UNIVERSITY
|
|
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors
|
1R21CA128421-01
|
$171,000
|
ADAMS, GREGORY
|
FOX CHASE CANCER CENTER
|
|
HOWARD UNIVERSITY CANCER CENTER/JOHNS HOPKINS CANCER CENTER PARTNERSHIP
|
5U54CA091431-07
|
$1,410,542
|
ADAMS-CAMPBELL, LUCILE
|
HOWARD UNIVERSITY
|
|
A Transgenic Model for Prostate Tumor Immunity
|
5R01CA109339-04
|
$281,848
|
ADLER, ADAM
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
MMC and VICC: Partners in Eliminating Cancer Disparities
|
5U54CA091408-07
|
$1,882,399
|
Adunyah, Samuel
|
MEHARRY MEDICAL COLLEGE
|
|
Colon Cancer Chemoprevention by Flavonoid Silibinin
|
5R01CA112304-03
|
$284,889
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER/HSC AURORA
|
|
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis
|
1R01CA124940-01A1
|
$250,515
|
AGAZIE, YEHENEW
|
WEST VIRGINIA UNIVERSITY
|
|
Targeting Relaxin Signaling in Prostate Cancer
|
1R21CA118362-01A1
|
$180,000
|
Agoulnik, Alexander
|
BAYLOR COLLEGE OF MEDICINE
|
|
Clinical study of GMCI in Pancreatic Cancer
|
5R43CA119847-02
|
$376,666
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Functional determinants of metastatic dormancy
|
5R01CA109182-03
|
$301,013
|
AGUIRRE-GHISO, JULIO
|
STATE UNIVERSITY OF NEW YORK AT ALBANY
|
|
Phase III Trial of Selenium for Prostate Cancer Prevention
|
5R01CA077789-09
|
$605,351
|
Ahmann, Frederick
|
UNIVERSITY OF ARIZONA
|
|
Signal Transduction Pathways in Melanoma
|
1R01CA118972-01A2
|
$268,850
|
AHN, NATALIE
|
UNIVERSITY OF COLORADO AT BOULDER
|
|
Genomewide association in early-onset breast cancer
|
7U01CA122171-02
|
$2,001,589
|
AHSAN, HABIBUL
|
UNIVERSITY OF CHICAGO
|
|
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
|
1R01CA116019-01A2
|
$295,961
|
AKHURST, ROSEMARY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog
|
1R01CA120552-01A1
|
$258,210
|
AKPORIAYE, EMMANUEL
|
UNIVERSITY OF ARIZONA
|
|
A Novel Regulator of Cancer Cell Migration and Invasion
|
5R01CA115706-02
|
$195,792
|
ALAHARI, SURESH
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
Defining the role of Id1 in melanoma development
|
5R01CA107017-04
|
$244,169
|
ALANI, RHODA
|
JOHNS HOPKINS UNIVERSITY
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S1
|
$363,313
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S2
|
$113,227
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S3
|
$327,884
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S4
|
$88,172
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
CHEMOPREVENTION OF SKIN CANCER PROGRAM PROJECT
|
5P01CA027502-26
|
$3,758,432
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center Support Grant
|
5P30CA023074-30
|
$4,124,404
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Genomic and Functional Analysis of Oral Cancer Development
|
1R01CA118323-01A2
|
$269,573
|
Albertson, Donna
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Cellular MRI in Glioma and Radiation Necrosis
|
1R01CA122031-01A2
|
$247,950
|
ALI, SYED
|
HENRY FORD HEALTH SYSTEM
|
|
Blood Flow MRI for Monitoring Glioma Angiogenesis
|
5R01CA115745-02
|
$333,543
|
ALSOP, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Blood Flow MRI for Monitoring of Renal Cell Carcinoma
|
5R21CA121570-02
|
$292,999
|
ALSOP, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Infectivity Enhanced Virotherapy For Ovarian Cancer
|
1R21CA128222-01
|
$275,500
|
Alvarez, Ronald
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Dietary Prevention of Cancer
|
5R01CA109269-04
|
$263,847
|
ANANT, SHRIKANT
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
Cadherin-p120 signaling in motility and invasiveness
|
5R01CA100467-04
|
$262,409
|
ANASTASIADIS, PANAGIOTIS
|
MAYO CLINIC COLL OF MED, JACKSONVILLE
|
|
MAMMARY GLAND BIOLOGY GRC
|
1R13CA128408-01
|
$5,000
|
ANDERSON, STEVEN
|
GORDON RESEARCH CONFERENCES
|
|
PI Signaling Role in Ephitelial/Mesenchymal Transition
|
5R01CA104708-04
|
$282,819
|
ANDERSON, RICHARD
|
UNIVERSITY OF WISCONSIN MADISON
|
|
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL - SCREENING
|
N01CN025516-085
|
$1,656,966
|
ANDRIOLE, GERALD
|
THE WASHINGTON UNIVERSITY
|
|
Extension of Radiotherapy Research
|
5P01CA006294-43
|
$1,506,020
|
ANG, K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Combination Immunotherapy for Lung Cancer
|
5R21CA117115-02
|
$280,935
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Reversal of 5-FU Resistance by Arsenic Trioxide in Colorectal Carcinoma
|
1R21CA117116-01A2
|
$290,541
|
ARDALAN, BACH
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Telomeres, Telomerase and Tumor Progerssion
|
5R01CA111691-03
|
$293,771
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
SPORE in Breast Cancer
|
5P50CA098131-05
|
$2,360,642
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
TGF-betas and Receptors and Human Breast Cells
|
5R01CA062212-12
|
$327,034
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
Erbb2 targeted antitumor strategies in breast cancer
|
5R01CA080195-09
|
$302,816
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
Cyclin D1 and Cell Adhesion
|
5R01CA072639-11
|
$259,881
|
ASSOIAN, RICHARD
|
UNIVERSITY OF PENNSYLVANIA
|
|
DF/HCC Renal Cancer SPORE
|
5P50CA101942-05
|
$2,330,598
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterization of the p53 Apoptotic Target Gene Perp
|
2R01CA093665-06A1
|
$283,177
|
ATTARDI, LAURA
|
STANFORD UNIVERSITY
|
|
VEGF-based Targeted Imaging of Tumor Vasculature
|
2R44CA113080-02A2
|
$545,177
|
Backer, Joseph
|
SIBTECH, INC.
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|